Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-2506PO plus riluzole versus placebo plus riluzole in early amyotrophic lateral sclerosis
NL-OMON31679Phase 2Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing ONO-2506PO plus riluzole with Placebo plus riluzole (2 arms). Started Jun 2007; status: active, not recruiting.
02
Drugs
arundic acid
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON31679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31679.